|
Re: Zenith Capital Corp. to Present on the Emerging Growth Conference on September 25, 2024
|
2
|
Zenith Epigenetics
|
Oct 08, 2024 02:35PM
|
|
Re: Zenith Capital Corp. to Present on the Emerging Growth Conference on September 25, 2024
|
1
|
Zenith Epigenetics
|
Oct 08, 2024 03:32PM
|
|
Re: Zenith Capital Corp. to Present on the Emerging Growth Conference on September 25, 2024
|
|
Zenith Epigenetics
|
Sep 25, 2024 02:26PM
|
|
Re: Zenith Capital Corp. to Present on the Emerging Growth Conference on September 25, 2024
|
|
Zenith Epigenetics
|
Sep 25, 2024 03:03PM
|
|
Re: Zenith Capital Corp. to Present on the Emerging Growth Conference on September 25, 2024
|
|
Zenith Epigenetics
|
Sep 25, 2024 04:04PM
|
|
Re: Zenith Capital Corp. to Present on the Emerging Growth Conference on September 25, 2024
|
2
|
Zenith Epigenetics
|
Sep 25, 2024 05:54PM
|
|
Re: Zenith Capital Corp. to Present on the Emerging Growth Conference on September 25, 2024
|
2
|
Zenith Epigenetics
|
Oct 15, 2024 01:09PM
|
|
Re: Zenith deal/rvx future/money?
|
2
|
Zenith Epigenetics
|
Nov 16, 2023 09:27AM
|
|
Re: Zenith Epigenetics and Newsoara Announce Initiation of a Randomized Phase 2b Metastatic Castration-Resistant Prostate Cancer Study
|
5
|
Resverlogix Corp.
|
Sep 24, 2021 10:19AM
|
|
Re: Zenith Epigenetics Announces Collaboration with NCI in Developing ZEN-3694 for Multiple Oncology Indications
|
3
|
Zenith Epigenetics
|
Oct 06, 2020 03:38PM
|
|
Re: Zenith Epigenetics Announces Collaboration with NCI in Developing ZEN-3694 for Multiple Oncology Indications
|
5
|
Zenith Epigenetics
|
Oct 05, 2020 03:01PM
|
|
Re: Zenith Epigenetics Announces Collaboration with NCI in Developing ZEN-3694 for Multiple Oncology Indications
|
3
|
Zenith Epigenetics
|
Oct 05, 2020 05:10PM
|
|
Re: Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck’s Immune Check Point Inhibitor KEYTRUDA
|
3
|
Zenith Epigenetics
|
Mar 15, 2021 10:22AM
|
|
Re: Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck’s Immune Check Point Inhibitor KEYTRUDA
|
3
|
Zenith Epigenetics
|
Mar 15, 2021 01:57PM
|
|
Re: Zenith Epigenetics Announces Start of Several National Cancer Institute (NCI)-Sponsored Oncology Clinical Trials
|
|
Zenith Epigenetics
|
Jul 07, 2022 08:20AM
|
|
Re: Zenith Epigenetics Announces Start of Several National Cancer Institute (NCI)-Sponsored Oncology Clinical Trials
|
|
Zenith Epigenetics
|
Jul 07, 2022 10:56AM
|
|
Re: Zenith Epigenetics is proud to announce the appointment Dr. Brad Thompson, PhD to our Board of Directors!
|
1
|
Zenith Epigenetics
|
Feb 08, 2022 04:38PM
|
|
Re: Zenith Epigenetics is proud to announce the appointment Dr. Brad Thompson, PhD to our Board of Directors!
|
2
|
Zenith Epigenetics
|
Feb 08, 2022 07:09PM
|
|
Re: Zenith Epigenetics is proud to announce the appointment Dr. Brad Thompson, PhD to our Board of Directors!
|
5
|
Zenith Epigenetics
|
Feb 07, 2022 12:37PM
|
|
Re: Zenith Epigenetics is proud to announce the appointment Dr. Brad Thompson, PhD to our Board of Directors!
|
1
|
Zenith Epigenetics
|
Feb 09, 2022 07:31PM
|
